Literature DB >> 23896481

Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations.

Alexander A Firsov1, Elena N Strukova, Darya S Shlykova, Yury A Portnoy, Varvara K Kozyreva, Mikhail V Edelstein, Svetlana A Dovzhenko, Mikhail B Kobrin, Stephen H Zinner.   

Abstract

In light of the concept of the mutant selection window, i.e., the range between the MIC and the mutant prevention concentration (MPC), MPC-related pharmacokinetic indices should be more predictive of bacterial resistance than the respective MIC-related indices. However, experimental evidence of this hypothesis remains limited and contradictory. To examine the predictive power of the ratios of the area under the curve (AUC24) to the MPC and the MIC, the selection of ciprofloxacin-resistant mutants of four Escherichia coli strains with different MPC/MIC ratios was studied. Each organism was exposed to twice-daily ciprofloxacin for 3 days at AUC24/MIC ratios that provide peak antibiotic concentrations close to the MIC, between the MIC and the MPC, and above the MPC. Resistant E. coli was intensively enriched at AUC24/MPCs from 1 to 10 h (AUC24/MIC from 60 to 360 h) but not at the lower or higher AUC24/MPC and AUC24/MIC ratios. AUC24/MPC and AUC24/MIC relationships of the areas under the time courses of ciprofloxacin-resistant E. coli (AUBCM) were bell-shaped. A Gaussian-like function fits the AUBCM-AUC24/MPC and AUBCM-AUC24/MIC data combined for all organisms (r(2) = 0.69 and 0.86, respectively). The predicted anti-mutant AUC24/MPC ratio was 58 ± 35 h, and the respective AUC24/MIC ratio was 1,080 ± 416 h. Although AUC24/MPC was less predictive of strain-independent E. coli resistance than AUC24/MIC, the established anti-mutant AUC24/MPC ratio was closer to values reported for Staphylococcus aureus (60 to 69 h) than the respective AUC24/MIC ratio (1,080 versus 200 to 240 h). This implies that AUC24/MPC might be a better interspecies predictor of bacterial resistance than AUC24/MIC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23896481      PMCID: PMC3811419          DOI: 10.1128/AAC.00578-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection.

Authors:  A P MacGowan; K E Bowker; M Wootton; H A Holt
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus.

Authors:  Y Dong; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

3.  Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model.

Authors:  A A Firsov; V M Chernykh; S M Navashin
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

4.  Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.

Authors:  Sara K Olofsson; Linda L Marcusson; Patricia Komp Lindgren; Diarmaid Hughes; Otto Cars
Journal:  J Antimicrob Chemother       Date:  2006-04-19       Impact factor: 5.790

5.  Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; G Cornaglia
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  Mutational specificity of a conditional Escherichia coli mutator, mutD5.

Authors:  R G Fowler; G E Degnen; E C Cox
Journal:  Mol Gen Genet       Date:  1974

7.  Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin.

Authors:  Elias Gebru; Myung-Jin Choi; Seung-Jin Lee; Dereje Damte; Seung Chun Park
Journal:  J Med Microbiol       Date:  2011-05-19       Impact factor: 2.472

8.  In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.

Authors:  Delphine Croisier; Manuel Etienne; Lionel Piroth; Emilie Bergoin; Catherine Lequeu; Henri Portier; Pascal Chavanet
Journal:  J Antimicrob Chemother       Date:  2004-08-18       Impact factor: 5.790

9.  Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.

Authors:  J T Lettieri; M C Rogge; L Kaiser; R M Echols; A H Heller
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

10.  Mutations in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans and animals.

Authors:  Yolanda Sáenz; Myriam Zarazaga; Laura Briñas; Fernanda Ruiz-Larrea; Carmen Torres
Journal:  J Antimicrob Chemother       Date:  2003-03-13       Impact factor: 5.790

View more
  10 in total

Review 1.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.

Authors:  Xin Li; Lin Wang; Xian-Jia Zhang; Yang Yang; Wei-Tao Gong; Bin Xu; Ying-Qun Zhu; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

3.  In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus.

Authors:  Alexander A Firsov; Maria V Golikova; Elena N Strukova; Yury A Portnoy; Andrey V Romanov; Mikhail V Edelstein; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

4.  Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.

Authors:  Elena N Strukova; Yury A Portnoy; Andrey V Romanov; Mikhail V Edelstein; Stephen H Zinner; Alexander A Firsov
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

5.  Selection of target mutation in rat gastrointestinal tract E. coli by minute dosage of enrofloxacin.

Authors:  Dachuan Lin; Kaichao Chen; Ruichao Li; Lizhang Liu; Jiubiao Guo; Wen Yao; Sheng Chen
Journal:  Front Microbiol       Date:  2014-09-04       Impact factor: 5.640

6.  Determination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and Valnemulin.

Authors:  Nan Zhang; Xiaomei Ye; Yuzhi Wu; Zilong Huang; Xiaoyan Gu; Qinren Cai; Xiangguang Shen; Hongxia Jiang; Huanzhong Ding
Journal:  PLoS One       Date:  2017-01-04       Impact factor: 3.240

7.  Preventing Data Ambiguity in Infectious Diseases with Four-Dimensional and Personalized Evaluations.

Authors:  Michelle J Iandiorio; Jeanne M Fair; Stylianos Chatzipanagiotou; Anastasios Ioannidis; Eleftheria Trikka-Graphakos; Nikoletta Charalampaki; Christina Sereti; George P Tegos; Almira L Hoogesteijn; Ariel L Rivas
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

8.  Comparing the minimum inhibitory and mutant prevention concentrations of selected antibiotics against animal isolates of Pasteurella multocida and Salmonella typhimurium.

Authors:  Jeanette M Wentzel; Louise J Biggs; Moritz Van Vuuren
Journal:  Onderstepoort J Vet Res       Date:  2022-01-10       Impact factor: 1.792

9.  Predicting drug resistance evolution: insights from antimicrobial peptides and antibiotics.

Authors:  Guozhi Yu; Desiree Y Baeder; Roland R Regoes; Jens Rolff
Journal:  Proc Biol Sci       Date:  2018-03-14       Impact factor: 5.349

10.  Antibiotic Development and the Evolving Role of Pharmacodynamics - As Good as It Gets?

Authors:  Glenn S Tillotson; Stephen H Zinner
Journal:  EBioMedicine       Date:  2015-06-12       Impact factor: 8.143

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.